Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203392
The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method, as long as Licensee has current exclusive rights thereto under this Agreement, except that the sublicensee may not be granted the right to further sublicense the technology.
IPSCIO Record ID: 273421
With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.
The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.
Product means Research Product and Clinical Product.
Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.
The patented CelutionÂ® family of products process patientsâ€™ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The CelutionÂ® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Licensee commercialization model is based on the sale of CelutionÂ® Systems and on generating recurring revenues from the single-use consumable sets.
Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytoriâ€™s core product, the CelutionÂ® System, provides physicians with clinical grade stem and regenerative cells.
IPSCIO Record ID: 382728
Licensor has the unique strength of combining stem cell research focused on different organs and developmental stages with leading expertise in cellular plasticity, epigenetics and disease models. This unique combination has led to breakthrough discoveries at the crossroads between disease models and repair, cellular plasticity and disease as well as reprogramming.
IPSCIO Record ID: 345978
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.